v3.26.1
Segment Reporting (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
USD ($)
Mar. 31, 2026
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Jun. 30, 2026
USD ($)
segment
Jun. 30, 2025
USD ($)
Segment Reporting [Abstract]            
Number of reportable segments | segment         1  
Number of operating segments | segment         1  
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]            
Total revenues $ 32,832   $ 6,869   $ 39,553 $ 13,911
Research and development 38,780   40,791   73,754 80,489
General and administrative 7,904   9,302   17,614 20,020
Net income (loss) 19,515 $ (36,774) (36,251) $ (41,036) (17,259) (77,287)
Main Segment            
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]            
Total revenues 32,832   6,869   39,553 13,911
Research and development 38,780   40,791   73,754 80,489
General and administrative 7,904   9,302   17,614 20,020
Other segment income (loss), net (55,790)   507   (59,125) 2,094
Net income (loss) (69,642)   (42,717)   (110,940) (84,504)
Lorigerlimab | Main Segment            
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]            
Research and development 6,120   10,547   13,579 19,425
MGC026 | Main Segment            
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]            
Research and development 7,198   2,961   14,003 8,914
MGC028 | Main Segment            
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]            
Research and development 10,179   4,742   16,573 8,676
Next-generation T-cell engagers | Main Segment            
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]            
Research and development 5,987   3,516   10,635 5,789
MGC030 | Main Segment            
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]            
Research and development 5,001   5,666   8,930 8,172
MGD024 | Main Segment            
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]            
Research and development 2,082   2,715   4,858 4,907
Vobramitanmab duocarmazine | Main Segment            
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]            
Research and development 198   4,387   585 12,653
ADC | Main Segment            
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]            
Research and development 26   2,058   89 3,857
Other programs | Main Segment            
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]            
Research and development $ 1,989   $ 4,199   $ 4,502 $ 8,096